Gain Therapeutics, Inc.
NASDAQ: GANX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gene Mack
- Employees
- 23
- Headquarters
- Bethesda, United States
- IPO year
- 2021
- Market cap
- $74.2M
- Website
- https://www.gaintherapeutics.com
Loading GANX…
Loading profile data…Frequently asked questions about GANX
What does Gain Therapeutics, Inc. (GANX) do?
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pin...
Where does GANX trade?
Gain Therapeutics, Inc. (GANX) trades on the NASDAQ Global Market.
What sector is GANX in?
Gain Therapeutics, Inc. (GANX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gain Therapeutics, Inc.?
Gene Mack is the chief executive officer of Gain Therapeutics, Inc. (GANX).
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc. is headquartered in United States.
Does GANX pay a dividend?
Gain Therapeutics, Inc. (GANX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GANX go public?
Gain Therapeutics, Inc. (GANX) completed its initial public offering in 2021.